Early Results (at 6 Months) with Intermittent Clarithromycin-Including Regimens for Lung Disease Due to Mycobacterium avium Complex

This publication has 15 references indexed in Scilit:

• A Randomized, Placebo‐Controlled Study of Rifabutin Added to a Regimen of Clarithromycin and Ethambutol for Treatment of Disseminated Infection with Mycobacterium avium Complex
  Clinical Infectious Diseases, 1999
• Randomized, Open‐Label Trial of Azithromycin Plus Ethambutol vs. Clarithromycin Plus Ethambutol as Therapy forMycobacterium aviumComplex Bacteremia in Patients with Human Immunodeficiency Virus Infection
  Clinical Infectious Diseases, 1998
• Varying Dosages of Rifabutin Affect White Blood Cell and Platelet Counts in Human Immunodeficiency Virus-Negative Patients Who Are Receiving Multidrug Regimens for Pulmonary Mycobacterium avium Complex Disease
  Clinical Infectious Diseases, 1996
• Azithromycin Activity Against Mycobacterium avium Complex Lung Disease in Patients Who Were Not Infected with Human Immunodeficiency Virus
  Clinical Infectious Diseases, 1996
• A Comparison of Two Regimens for the Treatment ofMycobacterium aviumComplex Bacteremia in AIDS: Rifabutin, Ethambutol, and Clarithromycin versus Rifampin, Ethambutol, Clofazimine, and Ciprofloxacin
  New England Journal of Medicine, 1996
• Prophylaxis against DisseminatedMycobacterium aviumComplex with Weekly Azithromycin, Daily Rifabutin, or Both
  New England Journal of Medicine, 1996
• Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients.
  American Journal of Respiratory and Critical Care Medicine, 1996
• Adverse Events Associated with High-Dose Rifabutin in Macrolide-Containing Regimens for the Treatment of Mycobacterium avium Complex Lung Disease
  Clinical Infectious Diseases, 1995
• Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease.
  American Journal of Respiratory and Critical Care Medicine, 1994
• Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system
  Antimicrobial Agents and Chemotherapy, 1992